$17.18
-1.8%CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
CBLL • NASDAQ
| CeriBell, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
ASSETS | ||||
CURRENT ASSETS | ||||
40.5M | 194.4M | 34.5M | 68.2M | |
118.8M | 0.0 | 0.0 | 0.0 | |
159.3M | 194.4M | 34.5M | 68.2M | |
15.1M | 10.9M | 8M | 5.3M | |
15.1M | 10.9M | 8M | 5.3M | |
7.3M | 6.9M | 5.9M | 4.1M | |
5.1M | 5.1M | 3.6M | 2.2M | |
186.7M | 217.3M | 52M | 79.8M | |
NON-CURRENT ASSETS | ||||
4.3M | 4.4M | 3.7M | 3.9M | |
805K | 0.0 | 0.0 | 0.0 | |
805K | 0.0 | 0.0 | 0.0 | |
4M | 3.7M | 3.2M | 2.8M | |
9.1M | 8.1M | 7M | 6.7M | |
195.8M | 225.4M | 58.9M | 86.5M | |
LIABILITIES | ||||
CURRENT LIABILITIES | ||||
2.8M | 1.1M | 732K | 423K | |
2.8M | 1.1M | 732K | 423K | |
0.0 | 5.7M | 4.4M | 3.5M | |
0.0 | 0.0 | 11.8M | 2.5M | |
1.1M | 1.1M | 694K | 629K | |
0.0 | 97K | 206K | 343K | |
15.2M | 5M | 3.7M | 2.5M | |
19.2M | 13M | 21.6M | 9.9M | |
NON-CURRENT LIABILITIES | ||||
19.8M | 19.6M | 0.0 | 12.7M | |
0.0 | 30K | 44K | 0.0 | |
106K | 356K | 147.9M | 147.9M | |
21.2M | 21.3M | 149.6M | 163M | |
2.5M | 2.4M | 2.4M | 3M | |
40.5M | 34.2M | 171.2M | 172.9M | |
SHAREHOLDERS' EQUITY | ||||
38K | 36K | 5K | 5K | |
375.5M | 358.1M | 14.2M | 10.6M | |
-220.4M | -166.9M | -126.5M | -97M | |
159K | 0.0 | 0.0 | 0.0 | |
155.3M | 191.2M | -112.3M | -86.4M | |
155.3M | 191.2M | -112.3M | -86.4M | |
SUMMARY | ||||
195.8M | 225.4M | 58.9M | 86.5M | |
118.8M | 0.0 | 0.0 | 0.0 | |
22.3M | 22M | 14.2M | 18.2M | |
-18.2M | -172.4M | -20.3M | -50M | |
37,095,690 | 37,095,690 | 37,095,690 | 37,095,690 |
CBLL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 02, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | June 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 05, 2026 | January 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | January 02, 2026 | December 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 12, 2025 | December 11, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 09, 2025 | December 09, 2025 | 2025 |
Continue your CBLL research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.